ProShare Advisors
AMAG

ProShare Advisors’s AMAG Pharmaceuticals AMAG Stock Holding History

ProShare Advisors’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,245
Closed -$78K – 1711
2020
Q2 		$78K Buy
+10,245
New +$78.4K ﹤0.01% 1598
2020
Q1 		– Sell
-12,830
Closed -$156K – 1742
2019
Q4 		$156K Sell
12,830
-1,038
-7% -$11.3K ﹤0.01% 1640
2019
Q3 		$160K Sell
13,868
-582
-4% -$6.13K ﹤0.01% 1482
2019
Q2 		$144K Sell
14,450
-2,036
-12% -$22K ﹤0.01% 1496
2019
Q1 		$212K Buy
16,486
+196
+1% +$2.92K ﹤0.01% 1442
2018
Q4 		$247K Sell
16,290
-2,840
-15% -$54.1K ﹤0.01% 1260
2018
Q3 		$383K Sell
19,130
-926
-5% -$21.1K ﹤0.01% 1233
2018
Q2 		$391K Sell
20,056
-1,840
-8% -$40.7K ﹤0.01% 1234
2018
Q1 		$441K Sell
21,896
-3,443
-14% -$58.2K ﹤0.01% 1151
2017
Q4 		$336K Buy
25,339
+2,365
+10% +$35.7K ﹤0.01% 1319
2017
Q3 		$424K Buy
22,974
+1,364
+6% +$25.4K ﹤0.01% 1027
2017
Q2 		$398K Sell
21,610
-1,531
-7% -$30.3K ﹤0.01% 1037
2017
Q1 		$522K Sell
23,141
-5,821
-20% -$139K 0.01% 989
2016
Q4 		$1.01M Buy
28,962
+3,279
+13% +$98K 0.01% 774
2016
Q3 		$629K Sell
25,683
-5,096
-17% -$127K 0.01% 854
2016
Q2 		$736K Buy
30,779
+37
+0.1% +$848 0.01% 816
2016
Q1 		$719K Sell
30,742
-2,191
-7% -$52K 0.01% 843
2015
Q4 		$994K Buy
32,933
+3,651
+12% +$118K 0.01% 739
2015
Q3 		$1.16M Buy
29,282
+1,033
+4% +$64.1K 0.02% 627
2015
Q2 		$1.95M Buy
28,249
+98
+0.3% +$6.17K 0.03% 527
2015
Q1 		$1.54M Buy
28,151
+7,117
+34% +$339K 0.02% 648
2014
Q4 		$896K Buy
21,034
+1,043
+5% +$37.7K 0.01% 914
2014
Q3 		$638K Sell
19,991
-3,952
-17% -$84.3K 0.01% 1262
2014
Q2 		$496K Sell
23,943
-14,593
-38% -$270K 0.01% 1594
2014
Q1 		$746K Buy
38,536
+27,389
+246% +$582K 0.01% 1542
2013
Q4 		$271K Sell
11,147
-10,099
-48% -$238K ﹤0.01% 1192
2013
Q3 		$456K Buy
21,246
+3,256
+18% +$76.9K 0.01% 1548
2013
Q2 		$400K Buy
+17,990
New +$396K 0.01% 1490

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ProShare Advisors's AMAG Position: Q3 2020 in Review

ProShare Advisors sold out of AMAG Pharmaceuticals (AMAG) in Q3 2020, closing a stake of 10,245 shares — an estimated $78K sold.

ProShare Advisors first reported a position in AMAG in Q2 2013 and held it in 28 quarters. The position peaked at $1.95M in Q2 2015. 113 funds tracked by Wall St. Rank hold AMAG as of Q3 2020.

  • ProShare Advisors reported no remaining AMAG Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • ProShare Advisors sold 10,245 AMAG Pharmaceuticals shares in Q3 2020, an estimated $78K.
  • ProShare Advisors first reported a position in AMAG Pharmaceuticals in Q2 2013 and held it in 28 quarters.
  • ProShare Advisors's AMAG Pharmaceuticals position peaked at $1.95M in Q2 2015.
  • 113 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q3 2020.

Based on ProShare Advisors's 13F filing for Q3 2020, filed 13 Nov 2020.